RSPO1 and neoplasm: In a human patient-derived xenograft mouse model harboring PTPRK–RSPO3 fusions, which amplify canonical Wnt signaling driven by WNTs, treatment with anti-RSPO antibodies led to reduced tumor volumes, loss of stem cell properties, and induction of differentiation [119].